RO Inline Sensor Integration Patent Landscape 2026
The RO inline sensor integration field is a mature, moderately concentrated niche with 118 patent families in scope, led by Veolia Water Solutions and a cluster of medical-device and water-treatment specialists. Filing activity has plateaued near its 2018 peak, with the United States as the dominant jurisdiction and separation-process chemistry accounting for the largest share of technical coverage.
Veolia leads a fragmented but specialist-heavy field
Veolia Water Solutions & Technologies Support SAS holds the leading position with 15 patent records, followed by Vantive Health GmbH, Vantive US Healthcare LLC, and Evoqua Water Technologies LLC each at 11 patent records, and Israel Aerospace Industries at 10 patent records.
The top five filers account for 25% of the combined total across the hundred largest filers, indicating a moderately concentrated field where no single player commands a dominant share. Several second-tier applicants — including Bonomics, Synauta, and. A. O. Smith — trail closely, suggesting the competitive tier is relatively flat below the leader.
| # | Applicant | Patent records | Share |
|---|---|---|---|
| 1 | VEOLIA WATER SOLUTIONS & TECHNOLOGIES SUPPORT SAS | 15 | |
| 2 | Vantive Health GmbH | 11 | |
| 3 | Vantive US Healthcare LLC | 11 | |
| 4 | Evoqua Water Technologies LLC | 11 | |
| 5 | Israel Aerospace Industries Ltd | 10 | |
| 6 | Bonomics Ltd | 9 | |
| 7 | Synauta Inc | 9 | |
| 8 | A.O. Smith Corporation | 8 | |
| 9 | Zenon Environmental Inc | 8 | |
| 10 | Mar Cor Purification Inc | 7 |
| # | Applicant | Patent records | Share |
|---|---|---|---|
| 11 | Abbott Laboratories | 7 | |
| 12 | Baxter Healthcare SA | 6 | |
| 13 | Baxter International Inc | 6 | |
| 14 | WaterChef Inc | 5 | |
| 15 | Zenon Tech Partnership | 4 | |
| 16 | Hospira Inc | 4 | |
| 17 | KOREA INST OF CIVIL ENG & BUILDING TECH | 4 | |
| 18 | Gambro Lundia AB | 4 | |
| 19 | Water Tech Ltd | 3 | |
| 20 | Katadyn Desalination LLC | 3 |
The spread of activity across water-treatment utilities, aerospace-adjacent desalination, and medical-device companies reflects the cross-industry applicability of inline sensing in RO systems; incumbents with established membrane portfolios appear best positioned to extend into sensor-integrated system claims.
Patent records published in the most recent 18–24 months are subject to publication lag and will be under-counted in this corpus; apparent softness in 2024–2026 data should not be interpreted as declining activity. Longer-window growth, applicant concentration, and technology-route coverage are therefore more reliable signals than the latest-year bar alone.
A 2018 filing surge has settled into a plateau; separation processes dominate the technology mix
The annual filing chart captures an irregular pattern anchored by a sharp 2018 spike, while the technology-composition chart reveals that two IPC classes — filtration/separation and water treatment — account for the large majority of coverage, with medical-device and analytical-testing branches forming a meaningful secondary cluster.
Annual filing trend
Filings peaked sharply in 2018 and have since settled at a lower plateau through 2023–2024; the 2025–2026 bars are subject to publication lag and should not be read as a further decline. The multi-year trajectory confirms maturity rather than growth.
↗ Hover for values · click a bar to ask EurekaTechnology composition
B01D (separation processes including filtration) and C02F (water and wastewater treatment) together dominate the IPC mix. A61M (devices for body fluids, covering dialysis and medical RO applications) and G01N (material analysis and testing, covering inline sensing instrumentation) form a secondary but strategically important tier. Remaining branches each represent very small shares, indicating a largely unfragmented technical agenda.
↗ Hover for values · click a bar to ask EurekaHighly cited patent families surfaced by the query
Citation-heavy patent families returned by the query. Use this section as citation context, not as a curated list of the most topic-specific patents.
Reverse osmosis system
A reverse osmosis system includes a first conductivity sensor for measuring electrical conductivity of water supplied to the reverse osmosis system, and a second conductivity sensor for measuring electrical conductivity of a permeate produced by the reverse osmosis system. The system also includes an AI unit designed to use a statistical model for… (excerpt from the patent abstract)
| # | Patent | Citations |
|---|---|---|
| 1 | Peritoneal dialysis system using reverse osmosis p… | 348 |
| 2 | Reverse osmosis purification system | 244 |
| 3 | Desalination method and apparatus utilizing nanofi… | 191 |
| 4 | Water purifying and vending apparatus | 168 |
| 5 | Portable water disinfection system | 137 |
| 6 | Water purification machine | 125 |
| 7 | Refrigerator with purified water supply | 120 |
| 8 | Medical drug formulation and delivery system and r… | 103 |
Ranked by total forward citations. Citation counts favour older and broadly cited patent families, and broad or adjacent patents may appear when they match the search scope. Treat this section as citation context, not as a curated list of the most topic-specific patents. Some patent titles may be shown in their original, non-English language where an accurate translation could not be guaranteed.
What the portfolio structure means for R&D investment decisions
The combination of a maturing filing curve, moderate concentration, active corporate co-filing in the medical segment, and US-led jurisdiction coverage shapes where differentiated investment can still generate freedom-to-operate advantages.
Field has plateaued near its 2018 peak
The lifecycle is classified as Maturity, with annual filings having plateaued near their 2018 peak and zero net growth in the recent window. Core separation-process claims in B01D and C02F are well-populated, reducing the scope for broad foundational patents. R&D investment is better directed toward incremental differentiation — sensor fusion, real-time data integration, or application-specific system architectures — rather than broad platform claims.
Lifecycle: MaturityModerate concentration with a flat challenger tier
The top five filers hold 25% of the combined total across the hundred largest filers, and the gap between the leader (15 patent records) and the fourth-ranked applicants (11 patent records each) is narrow. This flat tier structure means no challenger faces a prohibitive barrier to closing the gap with targeted prosecution. New entrants with application-specific sensor platforms — particularly in underserved branches — can realistically carve out defensible niches.
Concentration: ModerateBaxter–Vantive cluster dominates co-filing; Mar Cor and Evoqua form a water-treatment pair
The most active co-filing relationship is between Baxter International and Baxter Healthcare SA (10 shared filings), reflecting a corporate-family portfolio strategy. Baxter International also co-files with Vantive US Healthcare LLC and Vantive Health GmbH (4 filings each), reinforcing the medical-RO ecosystem cluster. Mar Cor Purification co-files with Evoqua Water Technologies LLC (2 filings), and Gambro Lundia co-files with multiple Baxter and Vantive entities, indicating that dialysis-adjacent RO sensing is managed through structured corporate alliances rather than open partnerships.
Collaboration: Corporate clustersUS-centric with meaningful EPO and PCT reach
The United States leads jurisdiction coverage with 53 patent records, followed by Europe via the EPO (32 records) and WIPO PCT filings (27 records). India and Australia each register notable coverage. China holds only 7 records and South Korea 6, suggesting that Asian manufacturing markets remain comparatively under-protected — a potential freedom-to-operate advantage for new entrants deploying inline sensor systems in those geographies.
Geography: US-ledGo beyond the landscape: Eureka’s TRIZ Solution agent breaks down an R&D problem and returns patented concept solutions, each with a technical approach and cited patent & literature evidence.
| Applicant | Collaborator | Co-filings |
|---|---|---|
| Baxter International Inc | Baxter Healthcare SA | 10 |
| Baxter International Inc | Vantive US Healthcare LLC | 4 |
| Baxter International Inc | Vantive Health GmbH | 4 |
| Baxter Healthcare SA | Vantive US Healthcare LLC | 4 |
| Baxter Healthcare SA | Vantive Health GmbH | 4 |
| Mar Cor Purification Inc | Evoqua Water Technologies LLC | 2 |
| Mar Cor Purification Inc | Evoqua Water Technologies Ltd | 2 |
| Gambro Lundia AB | Baxter International Inc | 2 |
| Gambro Lundia AB | Baxter Healthcare SA | 2 |
| Gambro Lundia AB | Vantive US Healthcare LLC | 2 |
Co-filing pairs, ranked by the number of jointly-filed patent families.
Veolia anchors water-treatment coverage; Baxter–Vantive cluster leads medical-RO sensing
The two most distinct strategic postures in this landscape are Veolia’s deep membrane-separation focus in industrial water treatment and the Baxter/Vantive corporate family’s concentration on medical-grade RO for dialysis applications.
Veolia Water Solutions & Technologies Support SAS
Veolia leads with 15 patent records, concentrated in B01D 61 (membrane separation processes) and C02F 1 (water and wastewater treatment) — the two dominant branches of this field. This focused technical profile reflects a deliberate strategy of protecting core RO system architectures with integrated sensing rather than diversifying into adjacent medical or analytical branches. No momentum data is available in the evidence for Veolia’s recent filing trajectory.
patent records: 15Baxter International & Vantive
Baxter International (11 patent records) and its associated entities Vantive US Healthcare LLC (11 records) and Vantive Health GmbH (11 records) together represent the largest collective presence in the field, concentrated in B01D 61, C02F 1, and A61M 1 (medical devices for body fluids). Both Baxter International and Baxter Healthcare SA are flagged as new entrants in recent filing momentum, suggesting the corporate family has recently accelerated prosecution — likely linked to the Vantive spin-off and independent portfolio buildout.
patent records: 11 each entity| Applicant | Recent (3 yrs) | Trend |
|---|---|---|
| Baxter International Inc | 5 | ▲ new entrant |
| Baxter Healthcare SA | 5 | ▲ new entrant |
| Synauta Inc | 1 | ▲ new entrant |
Under-served branches in medical sensing, analytical testing, and maritime applications
Several IPC branches appear in this corpus at low counts relative to the dominant separation and water-treatment classes, suggesting areas where RO inline sensor technology has been applied but not yet extensively patented. These are observations of relative sparsity and should be evaluated against technical feasibility and competitive context before committing R&D resources.
G01N · Material analysis & testing
G01N covers inline analytical instrumentation — conductivity, turbidity, pH, and contaminant sensing — which is directly relevant to real-time RO performance monitoring but accounts for only 22 patent records (roughly 5% of the IPC branch distribution). The dominant RO filers have not focused here, and the most-cited patent on peritoneal dialysis RO and the reverse osmosis purification system patent both imply demand for tighter in-line measurement. An entrant with strong analytical chemistry or sensor hardware IP could pursue G01N claims that underpin system-level monitoring without conflicting heavily with incumbent membrane patents.
Search this in Eureka →B63J · Ship auxiliaries (maritime RO sensing)
B63J appears with only 4 patent records, representing the smallest meaningful cluster in this corpus. Maritime and offshore desalination systems face unique sensing challenges — vibration, saltwater corrosion, variable feed quality — that onshore water-treatment patents do not address. A.O. Smith’s technology focus includes B63J 4, suggesting at least one incumbent has recognised this niche, but coverage remains sparse. For companies serving naval, offshore oil and gas, or cruise-industry water systems, this branch presents a technically plausible and lightly contested area to build defensible inline-sensor claims.
Search this in Eureka →How leading applicants differ by technology route
Route coverage across the main technology branches in the current evidence set.
| Player | B01D 61 · Separation processes (filtration etc.) | C02F 1 · Water & wastewater treatment | B01D 65 · Separation processes (filtration etc.) | A61M 1 · Devices for body fluids | B01D 63 · Separation processes (filtration etc.) |
|---|---|---|---|---|---|
| Abbott Laboratories | Strong · 11 | Strong · 11 | Absent | Strong · 11 | Strong · 11 |
| Mar Cor Purification Inc | Moderate · 7 | Strong · 15 | Strong · 10 | Moderate · 4 | Absent |
| Bonomics Ltd | Strong · 9 | Strong · 9 | Strong · 8 | Strong · 8 | Absent |
| Gambro Lundia AB | Strong · 13 | Strong · 13 | Absent | Moderate · 3 | Absent |
| Veolia Water Solutions & Technologies Support SAS | Strong · 15 | Strong · 13 | Absent | Absent | Absent |
| Zenon Environmental Inc | Strong · 7 | Strong · 6 | Strong · 6 | Absent | Strong · 6 |
| Israel Aerospace Industries Ltd | Strong · 10 | Strong · 8 | Strong · 6 | Absent | Absent |
Frequently asked questions
The corpus used for this analysis contains 118 patent families in scope globally.
Veolia Water Solutions & Technologies Support SAS leads with 15 patent records, ahead of Vantive Health GmbH, Vantive US Healthcare LLC, and Evoqua Water Technologies LLC, each with 11 patent records.
The United States leads with 53 patent records, followed by Europe via the EPO with 32 records and WIPO PCT filings with 27 records. India (18) and Australia (17) also have notable coverage, while China holds only 7 records.
The field is classified as Maturity. Annual filings have plateaued near their 2018 peak, and the recent-window growth rate is zero, indicating that foundational patent positions are largely established.
B01D (separation processes including filtration) and C02F (water and wastewater treatment) are the two dominant classes. A61M (devices for body fluids, covering medical RO and dialysis) and G01N (material analysis and testing, covering inline sensing instruments) form a secondary tier.
G01N (material analysis and testing for inline sensor instrumentation) accounts for only 22 patent records and is not a primary focus of the dominant water-treatment filers. B63J (ship auxiliaries, covering maritime desalination sensing) has only 4 patent records. Both branches are sparsely covered relative to the dominant classes and may warrant closer review for teams with relevant sensor or maritime-systems expertise.
Built on Patsnap Open Platform
This report’s underlying patent dataset — filings, assignees, technology clusters — is open for developers via MCP and REST API. Free to start, 10,000 credits, no credit card required.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.